IFNA1 and hepatocellular carcinoma: However, type of antiviral agent that induced SVR was not associated with HCC risk (vs. IFN-based therapy; adjusted HR, 4.289; 95% CI, 0.648–28.408; P = 0.13) and the risk of all-cause mortality (vs. IFN-based therapy; adjusted HR, 1.348; 95% CI, 0.208–8.735; P = 0.75) in the multivariable Cox model.